Mymetics Strengthens Virosome Vaccine Platform


New head of quality and manufacturing strengthens Mymetics’ virosome vaccine platform

March 10, 2014

Mymetics announced today that it has secured and further strengthened its know-how and leadership in the research and development of virosome based vaccines as well in manufacturing and IP.

Dr. Mario Amacker recently joined Mymetics as Head of Quality and Manufacturing, after having been member of the executive management team and head of process development and manufacturing at Pevion Biotech SA. Dr. Amacker brings a wealth of experience and know-how in the manufacturing, formulation and quality aspects of influenza based virosomes and is a very strong addition to the Mymetics management team.

Pevion Biotech SA was the exclusive manufacturer for Mymetics’ clinical stage HIV and malaria virosome vaccine candidates until they stopped operations. Consequently Mymetics has further secured the freedom to manufacture and obtained exclusive rights to the know-how, IP and materials related to the manufacturing of the promising HIV and malaria virosome based vaccines.

“We are very proud that Dr. Mario Amacker has decided to join Mymetics. He perfectly complements our strong scientific team: Dr. Toon Stegmann, CSO of Mymetics BV and Head of R&D and Dr. Sylvain Fleury, the CSO of Mymetics Corporation,” said Ronald Kempers, CEO of Mymetics Corporation. “With our recently announced license and collaboration agreement for the RSV virosome vaccine, financed by Astellas Pharma, one of the two leading pharmaceutical company in Japan, we are on the right track to build a solid but nibble virosome vaccine research and development company, with a strong pipeline of very promising prophylactic vaccine candidates for specific infectious diseases.”

Read more here.

Leave a Reply

Your email address will not be published. Required fields are marked *